Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | MB | P02144 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11740154 | 0.98 | TDP1 (0.55) | TDP1ALDH1A1CYP1A2PKMCA12 | |
| SCHEMBL33701 | 0.85 | PKM (0.59) | TDP1ALDH1A1CYP1A2PKMCA12 | |
| SCHEMBL29415477 | 0.85 | PKM (0.59) | TDP1ALDH1A1CYP1A2PKMCA12 | |
| SCHEMBL30442658 | 0.84 | TDP1 (0.60) | TDP1ALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL7509092 | 0.84 | TDP1 (0.60) | TDP1ALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL9818524 | 0.84 | ENPP2 (0.51) | TDP1ALDH1A1CYP1A2PKMCA12 | |
| Hydrochloric Acid SCHEMBL7155376 | 0.83 | PKM (0.57) | TDP1ALDH1A1CYP1A2PKMCA12 | |
| Hydrochloric Acid SCHEMBL7516181 | 0.82 | TDP1 (0.58) | TDP1ALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL3192352 | 0.82 | PKM (0.65) | TDP1ALDH1A1CYP1A2PKMCA12 | |
| SCHEMBL8921186 | 0.82 | PKM (0.64) | ALDH1A1PKMCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547713-B2 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2009-06-16 | — | — | US | claimed |
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2006-05-25 | — | — | US | claimed |
| CN-114269725-B | Anti-influenza virus compound, preparation method and application thereof | 西藏海思科制药有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20230079045-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| CN-114436876-B | Continuous synthesis method of 2-amino-4-acetamino anisole | 中国科学院大连化学物理研究所 | 2023-03-14 | — | — | CN | disclosed |
| CN-114436876-A | Continuous synthesis method of 2-amino-4-acetamino anisole | 中国科学院大连化学物理研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-114269725-A | Anti-influenza virus compound and preparation method and application thereof | 四川海思科制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-111039915-B | Raf kinase inhibitor, preparation method, pharmaceutical composition and application thereof | 北京鑫开元医药科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-113563217-A | Method for synthesizing N, N-diethyl-3-acetaminoaniline by using supergravity reactor and tubular reactor | 浙江迪邦化工有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113423398-A | MEK inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11040963-B2 | Piperazine derivatives for influenza virus inhibitions | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2021-06-22 | — | — | US | disclosed |
| EP-0144776-A2 | Fibre-reactive chromium complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-06-19 | — | — | EP | disclosed |
| EP-0142104-A2 | Fibre-reactive chromium complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-05-22 | — | — | EP | disclosed |
| EP-0141416-A2 | Fibre-reactive chromium complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-05-15 | — | — | EP | disclosed |
| EP-0079563-A2 | Water soluble 1:2 metal complex azo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-05-25 | — | — | EP | disclosed |
| EP-0069376-A2 | Copper complexes of monoazo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-12 | — | — | EP | disclosed |
| EP-0011048-B1 | A PROCESS FOR THE MANUFACTURE OF SUBSTANTIALLY PURE 3-AMINO-4-ALKOXY-ACYLANILIDES FROM 2,4-DINITROCHLOROBENZENE | Toms River Chemical Corporation (US) | 1982-01-27 | — | — | EP | disclosed |
| US-4283556-A | Process for the manufacture of substantially pure 3-amino-4-alkoxy-acylanilides from 2,4-dinitrochlorobenzene | TOMS RIVER CHEMICAL CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| EP-0011048-A1 | A process for the manufacture of substantially pure 3-amino-4-alkoxy-acylanilides from 2,4-dinitrochlorobenzene | Toms River Chemical Corporation (US) | 1980-05-14 | — | — | EP | disclosed |
| US-3985763-A | DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | PTGS2, PTGES2, PTGES | TDP1 3288/4885ALDH1A1 483/4885CYP1A2 8/4885 |
| US-11040963-B2 | Piperazine derivatives for influenza virus inhibitions | HAVCR2, BAZ2A, MAVS | TDP1 4859/4885ALDH1A1 631/4885CYP1A2 1856/4885 |
| US-20230079045-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | IDE, ACE, SI | TDP1 4524/4885ALDH1A1 1085/4885CYP1A2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.